Article - 02/09/2019 Call for a comprehensive master plan for preventing and treating cancer While a cancer-free world may seem unrealistic given the increasing numbers of cancer cases, we need to reach a social consensus that cancer deaths are unacceptable and that everything possible must be done to prevent them. Leading cancer researchers around the world are calling for more investment in prevention research and cancer screening to move towards the vision of a near cancer-free world.https://www.gesundheitsindustrie-bw.de/en/article/news/call-for-comprehensive-master-plan-preventing-treating-cancer
Article - 05/03/2019 Vaccination against oncogenic Epstein-Barr viruses Almost all humans are infected with Epstein-Barr viruses (EBV), which are linked to the development of benign diseases such as infectious mononucleosis as well as several cancers. Scientists from the German Cancer Research Center have developed a new strategy for creating a vaccine that targets different EBV virus life phases and has the potential to provide effective protection against EBV infection.https://www.gesundheitsindustrie-bw.de/en/article/news/vaccination-against-oncogenic-epstein-barr-viruses
Article - 08/08/2018 Ludolph: diagnosing and treating neurodegenerative disorders Ulm has long been a world leader in diagnosing and treating rare neurological disorders, notably amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and Huntington's disease (HD). We spoke with Professor Albert C. Ludolph, spokesperson for the Ulm DZNE site, medical director of the Clinic for Neurology at the RKU (University and Rehabilitation Clinics of Ulm) and world-renowned ALS researcher.https://www.gesundheitsindustrie-bw.de/en/article/news/ludolph-diagnosing-and-treating-neurodegenerative-disorders
Article - 05/04/2018 Crossing the valley of death with translational cancer research It can take many decades before promising research results become therapies that have a positive effect on cancer patients. Most research projects go adrift somewhere between the laboratory and the bedside in the so-called "valley of death". Projects carried out at the DKFZ show that translational cancer research actually works.https://www.gesundheitsindustrie-bw.de/en/article/news/crossing-the-valley-of-death-with-translational-cancer-research
Press release - 21/02/2018 German Cancer Award for Michael Baumann Michael Baumann, Chairman and Scientific Director of the German Cancer Research Center (DKFZ) in Heidelberg, receives the 2017 German Cancer Award in the category "Translational Research". The science award, which is sponsored by the German Cancer Society and the German Cancer Foundation, is one of the most prestigious distinctions in cancer medicine in Germany.https://www.gesundheitsindustrie-bw.de/en/article/press-release/german-cancer-award-for-michael-baumann
Event - 27/11/2017 Meet & Match: Strategies for Drug Discovery: Simulation – Screening – Repurposing Strasbourg, France, Registration deadline: 23/11/2017, Meet & Match https://www.gesundheitsindustrie-bw.de/en/event/drugdiscovery
Article - 22/09/2014 Experience report: Six months Shanghai Sebastian Giese, a doctoral student at the University of Freiburg, spent six months in Shanghai with funding from a Baden-Württemberg Ministry of Science, Research and the Arts China scholarship. Below, Sebastian tells us about his impressions of the country and its people and his experiences in the megacity.https://www.gesundheitsindustrie-bw.de/en/article/news/experience-report-six-months-shanghai
Article - 19/05/2014 Alcoholism: the molecular basis of addiction and deprivation Scientists at the Central Institute of Mental Health in Mannheim use rats and mice to study the genetic basis and neurobiological mechanisms of alcohol addiction, the changes that occur during alcohol deprivation and the factors that favour a relapse. In translational research, the results from animal experiments are reviewed using alcohol-dependent patients in order to turn them quickly into preventive strategies and therapies.https://www.gesundheitsindustrie-bw.de/en/article/news/alcoholism-the-molecular-basis-of-addiction-and-deprivation
Press release - 15/01/2014 Hit Discovery Constance GmbH: a new hub for HTS and compound management Hit Discovery Constance GmbH (“HDC”), a new joint venture organisation between Lead Discovery Center (Dortmund/Germany), Centre for Drug Design and Discovery (CD3, KULeuven, Leuven/Belgium) and Axxam (Milan/Italy) has started its operation. The new company is based in Constance (Germany) and will make use of the already established equipment and know-how of the former Takeda/Nycomed/Altana screening and compound management facilities at the site.https://www.gesundheitsindustrie-bw.de/en/article/press-release/hit-discovery-constance-gmbh-a-new-hub-for-hts-and-compound-management
Article - 18/11/2013 The HAE Accelerator – "compete to speed up your start-up" The HAE Accelerator is an international programme involving biomedical clusters in Cambridge (UK), Leuven (Belgium) and Heidelberg (Germany) that seeks to identify, train and put innovative start-up teams in the three countries in contact with international VC investors. Of the three business ideas that were awarded a HAE Investors’ Choice Award in September 2013, InoCard from Heidelberg came first with a new gene therapy for myocardial…https://www.gesundheitsindustrie-bw.de/en/article/news/the-hae-accelerator-compete-to-speed-up-your-start-up
Article - 09/09/2013 The Heinrich-Lanz Centre for Personalised Medicine in Mannheim A Centre for Translational Research and Personalised Medicine is currently emerging at the Faculty of Medicine in Mannheim, University of Heidelberg. The new centre is expected to boost the development of new therapies in cooperation with partners from Germany and abroad. The centre also works closely with the “French-German Advanced Translational Drug Discovery Center”, a unique, large-scale, cross-border research cooperation between French and…https://www.gesundheitsindustrie-bw.de/en/article/news/the-heinrich-lanz-centre-for-personalised-medicine-in-mannheim
Article - 12/11/2012 Otmar D. Wiestler – combining excellent research and cancer medicine The University of Tübingen Medical Faculty’s award of an honorary doctorate to the Chairman of the Executive Board of the German Cancer Research Center, Professor Dr. Otmar D. Wiestler, was not just a distinction awarded to a renowned neuropathologist, oncologist and stem cell researcher, it also honoured a well-known personality who has made a significant contribution to shaping health research in Germany.https://www.gesundheitsindustrie-bw.de/en/article/news/otmar-d-wiestler-combining-excellent-research-and-cancer-medicine
Article - 09/01/2012 Nutritional medicine: Can certain foods help treat cancer? Researchers at the Centre for Nutritional Medicine (ZEM), a joint institution of the Universities of Hohenheim and Tübingen, are investigating whether and to what extent certain food components can support the treatment of cancer and are hoping to derive scientifically founded dietary recommendations from their findings.https://www.gesundheitsindustrie-bw.de/en/article/news/nutritional-medicine-can-certain-foods-help-treat-cancer
Article - 19/12/2011 Gundram Jung – a pioneer in antibody-mediated cancer immunotherapy Physicist, medical doctor, researcher and now also a founder of a company – Professor Dr. Gundram Jung’s career has never gone in a completely straight line although his goal has always been the same: to develop innovative immunotherapies for the treatment of cancer. Jung’s genetically modified antitumour antibodies are now close to clinical application. https://www.gesundheitsindustrie-bw.de/en/article/news/gundram-jung-a-pioneer-in-antibody-mediated-cancer-immunotherapy
Article - 12/09/2011 TransLimm brings new immunotherapies to patients more rapidly With the establishment of the Center for Translational Immunology TransLimm the University of Tübingen has initiated a network whose objective is to quickly and effectively transfer innovative therapies into clinical application. Patients suffering from acute leukaemia might soon benefit from therapies involving antibodies optimized by recombinant antibody technology. https://www.gesundheitsindustrie-bw.de/en/article/news/translimm-brings-new-immunotherapies-to-patients-more-rapidly
Press release - 27/06/2011 NMI TT GmbH – creating value from research NMI TT GmbH is a subsidiary of the NMI Natural and Medical Sciences Institute in Reutlingen with which it works closely. Developments by the renowned NMI are commercialised by NMI TT GmbH and the profit flows back into the NMI’s research activities – thus leading to a value creation cycle that benefits research and development as well as the economy.https://www.gesundheitsindustrie-bw.de/en/article/press-release/nmi-tt-gmbh-creating-value-from-research
Dossier - 30/05/2011 Knowledge and technology transfer as a social responsibility Technology transfer that efficiently exploits the intellectual property created by publicly funded research is necessary in order to turn scientific discoveries into successful innovations that improve people’s quality of life and boost the economy. The efforts made to rapidly transfer research results from the laboratory into clinical application for the benefit of patients leads to new strategic partnerships and structures in the field of…https://www.gesundheitsindustrie-bw.de/en/article/dossier/knowledge-and-technology-transfer-as-a-social-responsibility
Article - 30/05/2011 From bench to bedside to bench The term translational medicine does not always refer to the concept “from bench to bedside and back”, and indeed is often used to refer to many other, somewhat distant, concepts. However, the new translation centres and translational research consortia do correspond to the original meaning. These new centres and consortia have become effective structures in health research in Germany whose goal is the continuous improvement of the diagnostic and…https://www.gesundheitsindustrie-bw.de/en/article/news/from-bench-to-bedside-to-bench
Article - 06/03/2011 Heidelberg Translational Lung Research Centre University and non-university research institutions in Heidelberg that carry out research into lung diseases have established an expert network – the Heidelberg Translational Lung Research Centre – which is part of the new BMBF-funded German Centre for Lung Research. In Heidelberg, research focuses on the development and treatment of cystic fibrosis, chronic obstructive pulmonary diseases and lung cancer. https://www.gesundheitsindustrie-bw.de/en/article/news/heidelberg-translational-lung-research-centre
Press release - 10/02/2011 Blood-clotting protein linked to cancer and septicaemia Scientists at the EMBL and the University of Heidelberg have shown how stressed cells boost the production of the blood-clotting protein thrombin and how cancer cells may be taking advantage of this process. This research could lead to new therapies.https://www.gesundheitsindustrie-bw.de/en/article/press-release/blood-clotting-protein-linked-to-cancer-and-septicaemia
Article - 03/12/2010 Review: Science meets Business Day 2010 (part I) Germinating seeds biosensors in the human body deaf people learning to hear again and new approaches to combat the flu virus the lectures held at the Science meets Business Day which concluded this years BioValley Science Week once again highlighted the innovations brought about through the joint efforts of research and industrial players on the Upper Rhine. https://www.gesundheitsindustrie-bw.de/en/article/news/review-science-meets-business-day-2010-part-i
Article - 29/11/2010 Going through the eye of a needle: Translating research findings into individualised patient treatment Anyone attempting to assess the importance of pharmacogenetics for drug safety will inevitably end up considering the ambiguous responses of Radio Eriwan. It is true that genetic tests are theoretically able to predict whether an inactive enzyme affects the metabolism of a drug and whether it is necessary to apply a different drug dose. But how can this knowledge be applied in everyday clinical settings when patients with this inactive enzyme are…https://www.gesundheitsindustrie-bw.de/en/article/news/going-through-the-eye-of-a-needle-translating-research-findings-into-individualised-patient-treatmen
Press release - 19/11/2010 Affimed enrols first patients in Phase I Hodgkin’s lymphoma study The Heidelberg-based biotech company Affimed Therapeutics AG announced on 15th November 2010 that the first Hodgkin’s lymphoma patients have been treated with the AFM13 TandAb® antibody in a Phase I clinical study. Thus, the “first-in-man” tetravalent, bispecific antibody based on the company’s proprietary RECRUIT-TandAb® antibody technology has entered the clinic.https://www.gesundheitsindustrie-bw.de/en/article/press-release/affimed-enrols-first-patients-in-phase-i-hodgkin-s-lymphoma-study
Press release - 12/10/2010 Clarification of stem cell migration – hope for more effective bone marrow transplants Researchers from the University of Ulm, Germany, and the Cincinnati Children’s Hospital Medical Center, USA, have shown that pharmacological inhibition of a signalling pathway triggered by EGFR (epidermal growth factor receptor) increased the mobilisation of haematopoietic stem cells in mice.https://www.gesundheitsindustrie-bw.de/en/article/press-release/clarification-of-stem-cell-migration-hope-for-more-effective-bone-marrow-transplants
Article - 24/05/2010 A long path from development to worldwide acceptance In cooperation with the Johns Hopkins Bloomberg School of Public Health Baltimore the University of Constance has established the Centre for Alternatives to Animal Testing Europe CAAT-EU in Constance. The goal of the transatlantic cooperation is to establish new and innovative methods to replace the use of laboratory animals in studies to combine the skills of the partners to provide a better safer and more human future for humans and animals…https://www.gesundheitsindustrie-bw.de/en/article/news/a-long-path-from-development-to-worldwide-acceptance